Radiation Induced Lung Injury (RILI) Clinical Trial
— RILIOfficial title:
Hyperpolarized 129Xe Magnetic Resonance Imaging for Evaluation of Radiation-Induced Lung Injury in Subjects Undergoing Thoracic Irradiation
Verified date | November 2023 |
Source | The Hospital for Sick Children |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
The purpose of this work is to perform hyperpolarized (HP) 129Xe MRI in human subjects undergoing thoracic radiation therapy (RT), both before, during and following RT. HP 129Xe MR images will be analysed to provide maps of ventilation (V), perfusion (Q), apparent diffusion coefficient (ADC) and gas exchange. These results will be combined to yield a new measure of RILI, (i.e. dose volume histograms; DVHV/Q) and compared with conventional dose volume histograms (DVH), pulmonary function tests (PFTs), quality of life (QOL) questionnaire and CT measurements for assessment of RILI at each time point. The aim is to development a novel method for early and more sensitive method of detecting RILI before irreversible lung damage happens.
Status | Terminated |
Enrollment | 1 |
Est. completion date | April 12, 2023 |
Est. primary completion date | April 12, 2023 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria:a) Patients 18 years of age or older; b) Diagnosis of locally advanced lung/esophageal/laryngeal or other type of cancer requiring radical intent RT to the thorax (with or without concurrent chemotherapy), consisting of 1.8 - 2 Gy daily fractions delivered over 5 - 6 weeks; c) Eastern Cooperative Oncology Group performance status 0 or 1; d) Preserved lung function as determined by a forced expiratory volume in 1 second (FEV1) > 70% to exclude patients with existing respiratory disorders (e.g. COPD, asthma etc.) Exclusion Criteria:a) Planned anti-cancer surgery after radical RT; b) Chronic use of corticosteroids; c) Any previous RT to the thorax; d) History of ataxia telangiectasia or other known conditions that may increase radio-sensitivity; e) Planned for other anticancer therapy apart from RT or concurrent chemotherapy/RT f) Currently pregnant or lactating; g) Psychiatric or addictive disorders that would preclude obtaining informed consent or adherence to protocol; h) Inability to travel to obtain MRI scans; i) Any contraindications to MRI including but not limited to severe claustrophobia, implanted devices, aneurysm clips, neurostimulators (patients will be prescreened prior to registration). - |
Country | Name | City | State |
---|---|---|---|
Canada | The Hospital for Sick Children | Toronto | Ontario |
Lead Sponsor | Collaborator |
---|---|
The Hospital for Sick Children |
Canada,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | DVHV/Q | In-house software will be used to generate the ventilation, perfusion and gas exchange maps and calculate DVHV/Q | 2 years |